Engineers Gate Manager LP Has $1.92 Million Position in Immunocore Holdings PLC Sponsored ADR $IMCR

Key Points

• Engineers Gate Manager LP increased its Immunocore stake by 334.3% in the second quarter, holding 60,327 shares valued at approximately $1.92 million. Institutional investors collectively own 84.5% of IMCR.
• Analyst sentiment is mixed but leans positive: Immunocore has an average “Moderate Buy” rating and a consensus price target of $56.38, despite recent downgrades to “Hold” and a “Sell” rating.
• IMCR opened at $31.77, within a 12-month range of $27.56 to $40.71. The company slightly missed quarterly EPS estimates, reporting a loss of $0.02 per share versus expectations of a $0.01 loss.

Engineers Gate Manager LP grew its holdings in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR - Free Report) by 334.3% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 60,327 shares of the company's stock after buying an additional 46,435 shares during the quarter. Engineers Gate Manager LP owned approximately 0.12% of Immunocore worth $1,915,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in the business. Armistice Capital LLC grew its holdings in Immunocore by 33.3% during the 4th quarter. Armistice Capital LLC now owns 1,098,000 shares of the company's stock worth $38,112,000 after acquiring an additional 274,000 shares during the last quarter. Fiera Capital Corp raised its stake in shares of Immunocore by 31.4% in the fourth quarter. Fiera Capital Corp now owns 1,044,831 shares of the company's stock worth $36,266,000 after acquiring an additional 249,674 shares during the last quarter. Janus Henderson Group PLC lifted its position in shares of Immunocore by 30.9% during the first quarter. Janus Henderson Group PLC now owns 594,712 shares of the company's stock worth $17,919,000 after purchasing an additional 140,308 shares in the last quarter. Braidwell LP bought a new stake in shares of Immunocore during the second quarter valued at approximately $16,552,000. Finally, TD Asset Management Inc increased its holdings in shares of Immunocore by 1.4% in the fourth quarter. TD Asset Management Inc now owns 292,764 shares of the company's stock valued at $10,162,000 after purchasing an additional 3,904 shares in the last quarter. 84.50% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on IMCR shares. Morgan Stanley set a $43.00 price objective on Immunocore in a report on Friday, August 7th. Wall Street Zen lowered Immunocore from a "buy" rating to a "hold" rating in a research note on Tuesday, July 28th. Zacks Research cut Immunocore from a "strong-buy" rating to a "hold" rating in a report on Thursday, September 3rd. TD Cowen upgraded Immunocore to a "strong-buy" rating in a research report on Monday, August 24th. Finally, Weiss Ratings reissued a "sell (e+)" rating on shares of Immunocore in a report on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $56.38.

Immunocore Stock Performance

IMCR stock opened at $31.77 on Wednesday. Immunocore Holdings PLC Sponsored ADR has a twelve month low of $27.56 and a twelve month high of $40.71. The company has a quick ratio of 4.44, a current ratio of 4.47 and a debt-to-equity ratio of 0.94. The company has a market cap of $1.64 billion, a P/E ratio of -85.86 and a beta of 0.74. The business's fifty day moving average is $34.74 and its 200-day moving average is $31.80.

Immunocore (NASDAQ:IMCR - Get Free Report) last released its quarterly earnings data on Friday, August 7th. The company reported ($0.02) EPS for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.01). Immunocore had a negative net margin of 4.20% and a negative return on equity of 4.54%. Equities research analysts forecast that Immunocore Holdings PLC Sponsored ADR will post 0.06 EPS for the current year.

Immunocore Profile

Immunocore Holdings plc is a biotechnology company that develops T-cell receptor (TCR) therapies designed to direct the immune system against cancer and other serious diseases. Its ImmTAC platform uses engineered TCRs to recognize disease-related peptides presented on the surface of cells and recruit T cells to destroy targeted cells.

The company's lead product is KIMMTRAK (tebentafusp-tebn), an ImmTAC therapy approved in the United States, European Union and other markets for the treatment of unresectable or metastatic uveal melanoma in certain patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.